Product Pipeline
Translyx Limited supports the introduction of innovative diagnostic and clinical products to New Zealand healthcare providers. The company works with healthcare organisations, laboratories, and academic partners to make globally validated clinical innovations available across hospital, community, and research settings.
Antibacterial Resistance
Antibacterial resistance remains an urgent public health concern even in New Zealand. While overall resistance rates here are lower than in some neighbouring regions, resistant strains are increasingly detected.
Learn more
Sepsis
Sepsis is a leading cause of serious illness and death, and it places a heavy burden on healthcare systems in New Zealand and internationally. In Aotearoa, sepsis is responsible for tens of thousands of infections annually.
Learn more
Oncology Biomarkers
Cancer remains a significant health challenge in New Zealand, with more than 30,000 people expected to be diagnosed each year in 2025. Accurate and timely biomarker testing is a cornerstone of modern oncology.
Learn more
Cardiac Biomarkers
Cardiovascular disease remains one of the leading causes of death and health burden in New Zealand. Cardiac biomarkers play a central role in diagnosing acute coronary syndromes and stratifying risk.
Learn more
Endocrine Biomarkers
Endocrine disorders such as diabetes, thyroid disease, and metabolic syndromes are highly prevalent in New Zealand. Accurate measurement of endocrine biomarkers is essential for diagnosing disease and guiding clinical interventions.
Learn more
Point of Care Testing
Point of care testing (POCT) is increasingly recognised as a vital part of modern healthcare delivery. POCT helps reduce turnaround times by providing diagnostic results near the patient.
Learn moreReady to Get Started?
Contact us to discuss how our services can support your technology adoption journey.